Skip to content

Pulmonary Hypertension Increases Risk of Poor Outcomes After Transcatheter Mitral Valve Repair

Key findings

  • In a nationwide U.S. registry study of 4,071 patients with severe mitral regurgitation who underwent transcatheter mitral valve repair with the MitraClip system, pulmonary hypertension (pHTN) was present in 73% of patients and was severe in 14%
  • Increasingly severe pHTN was associated with significantly increased risk of the primary endpoint, the composite of one-year all-cause mortality or readmission for heart failure
  • More severe pHTN was also significantly associated with one-year mortality and one-year readmissions considered separately, as well as with 30-day mortality
  • Even mild pHTN was associated with adverse clinical outcomes
  • Robust improvements in functional capacity occurred after transcatheter mitral valve repair, even among patients with severe pHTN, and the procedure was safe regardless of the severity of pHTN

Transcatheter mitral valve repair with the MitraClip system is approved by the FDA for patients with symptomatic, severe primary mitral regurgitation who are perceived to have prohibitive surgical risk. Pulmonary hypertension (pHTN) is common in such patients, but there are little data on how it affects the outcomes of valve repair.

In a large retrospective study, reported in JAMA CardiologyRasha Al-Bawardy, MD, MSc, interventional cardiology fellow, Sammy Elmariah, MD, MPH, interventional cardiologist in the Division of Cardiology at Massachusetts General Hospital, and colleagues documented increased mortality and readmission for heart failure after transcatheter mitral valve repair. However, even in patients with severe pHTN, the repair was safe and effective.

Study Methods

The researchers identified 4,071 patients across 232 centers from the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy registry who underwent nonemergent mitral valve repair using the MitraClip system between November 4, 2013 and March 31, 2017.

They were classified based on the following severity of pHTN:

  • Group 1 — No pHTN: mean pulmonary arterial pressure (mPAP) < 25 mm Hg (27% of patients)
  • Group 2 — Mild pHTN: mPAP of 25–34 mm Hg (34%)
  • Group 3 — Moderate pHTN: mPAP of 35–44 mm Hg (25%)
  • Group 4 — Severe pHTN: mPAP ≥ 45mm Hg (14%)

30-Day Outcomes

  • After multivariable adjustment, pHTN was independently associated with the composite outcome of 30-day all-cause mortality or heart failure-related readmission (HR for group 4 vs. group 1, 1.56; 95% CI, 0.99–2.42; P = .05)
  • When those outcomes were analyzed separately, 30-day mortality was associated with more severe pHTN (HR for group 4 vs. group 1, 2.81; 95% CI, 1.28–6.16; P = .01), but 30-day readmission rates did not differ significantly between groups
  • Robust improvements in New York Heart Association functional class were observed in all groups

One-Year Outcomes

  • The primary outcome, the composite of one-year mortality or readmission, occurred in 34% of all patients. Higher rates were noted with worsening pHTN (group 1, 28%; group 2, 32%; group 3, 36%; group 4, 45%; P < .001)
  • When analyzed separately, one-year mortality and readmission rates demonstrated similar patterns, with statistically significant differences between group 1 and group 4
  • The association of severe pHTN with increased incidence of the composite outcome persisted despite multivariable adjustment for potential confounders (HR for group 4 vs. 1, 1.44; 95% CI, 1.16–1.79; P < .001) and when modeled in a continuous manner (HR per 5-mm Hg increase in mPAP, 1.04; 95% CI, 1.01–1.07; P = .01)

A Hypothesis for Future Research

The relationships between severity of pHTN and adverse outcomes of mitral regurgitation suggest that treatment of mitral regurgitation occurred late in the disease course. Earlier intervention, before pulmonary hypertension develops, may result in improved outcomes.

of patients who had mitral valve repair with the MitraClip died or were readmitted for heart failure within one year

greater risk of mortality or readmission for heart failure within one year after mitral valve repair with the MitraClip in patients with severe pulmonary hypertension

greater risk of mortality or readmission for heart failure within 30 days after mitral valve repair with the MitraClip in patients with severe pulmonary hypertension

Learn more about the Heart Valve Program

Refer a patient to the Corrigan Minehan Heart Center

Related topics


The APOLLO Trial is investigating minimally invasive mitral valve replacement as an alternative to open heart surgery for patients with severe mitral valve regurgitation. Massachusetts General Hospital's team is leading efforts to explore the innovative procedure's safety and effectiveness.


Myocardial injury carries a worse prognosis than MI and warrants a thorough evaluation for its underlying precipitant.